WuXi Biologics Celebrates Inclusion in FTSE4Good Index for Fifth Year in a Row

WuXi Biologics Celebrated for Sustainability Achievement

WuXi Biologics, a premier global Contract Research, Development, and Manufacturing Organization (CRDMO), recently announced its inclusion as a constituent of the FTSE4Good Index Series for the fifth consecutive year. This continued recognition by FTSE Russell underscores the company's ongoing commitment to exceptional sustainability practices.

The FTSE4Good Index Series, initiated in 2001 by FTSE Russell, serves as a benchmark for measuring the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices. It is instrumental for investors aiming to align their portfolios with sustainable objectives. Inclusion in this esteemed index is based on an independent review of over 60 ESG criteria pertaining to corporate governance, environmental impact, labor practices, and more across both developed and emerging markets.

WuXi Biologics has shown impressive performance in various ESG categories, particularly excelling in corporate governance, anti-corruption measures, labor standards, and water security. Dr. Chris Chen, CEO of WuXi Biologics, expressed his pride: "Being selected again as a constituent of the FTSE4Good Index Series reinforces our commitment to driving sustainability across our operations and in our partnerships."

The company’s commitment to sustainability aligns closely with the United Nations Sustainable Development Goals (SDGs). WuXi Biologics actively collaborates with global initiatives, such as the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, to make tangible contributions to sustainability and social responsibility.

Recently, WuXi Biologics established ambitious greenhouse gas emissions reduction targets, recently validated by the Science Based Targets initiative (SBTi). This proactive approach demonstrates the organization's determination to not only meet but exceed environmental regulations and expectations.

In addition to being listed in the FTSE4Good Index, WuXi Biologics has received numerous accolades recognizing its sustainability efforts. The firm has been awarded the EcoVadis Platinum Medal and has been featured in various sustainability indices, including the Dow Jones Sustainability Index and CDP Water Security List. These recognitions highlight the company's dedication to maintaining high standards in all areas of ESG performance.

For WuXi Biologics, sustainability is not just a goal; it's a vital part of their business strategy. By employing over 12,000 skilled professionals spread across locations in China, the United States, Ireland, Germany, and Singapore, the company leverages its technological expertise to provide cost-effective and efficient service. As of December 31, 2024, WuXi Biologics supports 817 client projects, showcasing its capability in the biotech sector.

WuXi Biologics commits to creating shared value, leading the way in responsible practices that benefit not just shareholders but also the wider community and environment. The focus on innovative green technologies in their CRDMO solutions positions WuXi Biologics as a forerunner of sustainable business in the biopharmaceutical supply chain.

As the landscape of global health continues to evolve, the importance of sustainability in biotech will only grow. WuXi Biologics stands at the forefront of these developments, proving that businesses can thrive while championing social and environmental responsibility. With ongoing initiatives to enhance corporate social responsibility and eco-friendly practices, WuXi Biologics exemplifies how leadership in sustainability can be integrated into a successful business model. Expect to see continued excellence from this innovative leader in the years to come.